Efficacy and Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior Disease-Modifying Therapies: 3-Year Data From CASTING and LIBERTO (LIBERTO 1-Year Interim Results) (P5-4.003) | Publicación